Sagimet Biosciences, Inc. Class A (SGMT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on the stock and has a $42.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Debanjana Chatterjee has given her Buy rating due to a combination of factors related to Sagimet Biosciences’ denifanstat’s unique profile and market positioning. The drug, denifanstat, stands out because it does not share the same adverse effects as efruxifermin, particularly in terms of bone loss, which is a concern when combined with GLP-1 treatments that MASH patients are likely to use.
Given that denifanstat’s mechanism of action does not affect bone or muscle cells, it presents a safer option for long-term use in combination therapies. Furthermore, despite its competitive antifibrotic efficacy and favorable safety profile, Sagimet’s stock is currently undervalued compared to its peer AKRO, which provides a compelling investment opportunity. These elements collectively underscore the Buy recommendation for SGMT.
Chatterjee covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, AbSci, and Intellia Therapeutics. According to TipRanks, Chatterjee has an average return of -1.0% and a 34.48% success rate on recommended stocks.